Crysvita (burosumab-twza) Treatment
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Epidermal Nevus Syndrome
Conditions
Epidermal Nevus Syndrome
Trial Timeline
Jul 31, 2020 → Aug 31, 2021
NCT ID
NCT04320316About Crysvita (burosumab-twza) Treatment
Crysvita (burosumab-twza) Treatment is a approved stage product being developed by Ultragenyx Pharmaceutical for Epidermal Nevus Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04320316. Target conditions include Epidermal Nevus Syndrome.
What happened to similar drugs?
0 of 3 similar drugs in Epidermal Nevus Syndrome were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04320316 | Approved | Completed |
Competing Products
13 competing products in Epidermal Nevus Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 26 |
| Erlotinib | Astellas Pharma | Phase 2 | 27 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 21 |
| KRN23 | Kyowa Kirin | Phase 2 | 35 |
| SHR6390 + placebo | Jiangsu Hengrui Medicine | Phase 3 | 44 |
| ABT-414 | AbbVie | Pre-clinical | 26 |
| Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Merck | Phase 3 | 40 |
| Venetoclax + Fulvestrant | Roche | Phase 2 | 27 |
| Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine | Roche | Phase 3 | 40 |
| Palbociclib + Everolimus + Exemestane | Pfizer | Phase 1/2 | 32 |
| Palifermin | Swedish Orphan Biovitrum | Phase 1/2 | 24 |
| FDX104 (4% Doxycycline) | Vyne Therapeutics | Phase 2 | 25 |
| ATR-04 | Azitra | Phase 1/2 | 14 |